Post-Market Clinical Investigation of the Clareon® IOL

  • Research type

    Research Study

  • Full title

    Post-Market Clinical Investigation of the Clareon® IOL

  • IRAS ID

    236521

  • Contact name

    Mayank Nanavaty

  • Contact email

    mayank.nanavaty@nhs.net

  • Sponsor organisation

    Alcon Research Ltd

  • Clinicaltrials.gov Identifier

    NCT03316885

  • Duration of Study in the UK

    3 years, 7 months, 15 days

  • Research summary

    Research Summary
    The Clareon IOL (Model SY60WF) is a monofocal intraocular lens intended as a replacement of the human crystalline lens in adult patients following cataract surgery.

    The rationale to conduct this post-market study is to collect data on the safety and effectiveness of the Clareon IOL after 3 years from the surgery. These data are required to support Market Access requirements including the development of a product value dossier.
    The study will be conducted at 10-20 clinical sites worldwide, 2 sites are planned to be activated in the UK (both are NHS sites).
    Approximately 200 adult men and women diagnosed with cataract in both eyes will take part in the study. They will be implanted with an investigational lens Clareon and will attend a total of 12 study visits over a period of approximately 36 month: 1 preoperative screening visit (Visit 0); 2 operative visits (Visit 00 and Visit 00A) and 9 post-implantation visits (Visits 1-7A).
    Post-implantation visits will occur at the following intervals:
    Visit 1 and Visit 1A (Day 1-2 post-implantation, first and second eye),
    Visit 2 and 2A (Day 7-14 post-implantation, first and second eye),
    Visit 3A (Day 30-45 post-implantation from 2nd eye surgery),
    Visit 4A (Day 120-180 post-implantation from 2nd eye surgery),
    Visit 5A (Day 330-420 post-implantation from 2nd eye surgery),
    Visit 6A (Day 630-780 post-implantation from 2nd eye surgery),
    Visit 7A (Day 990-1140 post-implantation from 2nd eye surgery).
    Visit day calculations for Visits 1 and 2 are based off of the day of first eye surgery (Visit 00)and calculations for Visits 1A-7A are based off of the day of second eye surgery (Visit 00A).

    Unscheduled visits may be conducted if needed for medical attention.

    Summary of Results
    A lay summary was not planned at time of trial initiation.

  • REC name

    West Midlands - South Birmingham Research Ethics Committee

  • REC reference

    18/WM/0017

  • Date of REC Opinion

    12 Feb 2018

  • REC opinion

    Further Information Favourable Opinion